Cipla signs agreement with Takeda to commercialise Vonoprazan
This deal is meant to commercialise the drug in India under Cipla’s own trademark brands
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Cipla
Cipla gains USFDA approval for the generic version of Somatuline Depot (Lanreotide) injection
The new generic version to treat patients with GEP-NETs
Sanofi signs distribution pact with Cipla for CNS portfolio in India
Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium
Cipla receives USFDA approval for plazomicin injection in India
Plazomicin is a new Intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI)…
Cipla to further invest Rs 42 crore in GoApptiv
Strengthens investment in channels of the future to expand patient reach
NPPA slashes prices on 33 FDCs drugs
This move affects pharma companies like JB Chemicals, Eris Lifesciences, Zydus Healthcare, Cipla, Sun Pharma, Sanofi India, and…
Cipla recalls six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 MI) due to container…
The company said that it is initiating a recall in the US due to a market complaint for one single inhaler (Batch Number -…
Cipla strengthens its anti-diabetes portfolio through partnerships with MNCs: GlobalData
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01…
Cipla Q3 net profit rises seven per cent to Rs 808 crore
Its total revenue from operations rose to Rs 5,810 crore for the third quarter compared to Rs 5,479 in the year-ago period, Cipla…
Cipla and Ethris partner to develop mRNA-based therapies
A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris’s innovative…